Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non-small-cell lung cancer.

Notably, alpha diversity of the lower respiratory tract microbiome failed to reach significance by Shannon and Simpson index regardless of different clinical outcome‐oriented classifications (Figure 3A ; Figure S1C ), mainly contributing to restricted cohorts enrolled in this study, while the tendencies did remain.

also in 4,113 other papers